Prgn-3006 T Cells
Myelodysplastic Syndromes
Precigen, IncCell therapyPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 65/ 100
Competitive context
314 Active assets in the Myelodysplastic Syndromes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 4 | BB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Anti-Thymoglobulin, Rabbit Peking University First Hospital | Phase 2/3 | BB |
Daunorubicin OHSU Knight Cancer Institute | Phase 3 | BB |
FILGRASTIM City of Hope Medical Center | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Prgn-3006 T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →